Premium
Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis
Author(s) -
Frederiksen Birgitte,
Pressler Tacjana,
Hansen Annelise,
Koch Christian,
Høiby Niels
Publication year - 2006
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1080/08035250600752466
Subject(s) - medicine , cystic fibrosis , aerosolization , pulmonary function testing , respiratory disease , antibiotics , gastroenterology , respiratory tract , lung , respiratory system , pulmonary fibrosis , staphylococcus aureus , respiratory tract infections , pancreatic disease , inhalation , anesthesia , microbiology and biotechnology , bacteria , genetics , biology , pancreas
Background: Aerosolized recombinant human deoxyribonuclease (rhDNase I (Pulmozyme®)) has previously been shown to increase pulmonary function and reduce exacerbations of respiratory symptoms in cystic fibrosis (CF) patients with moderate to severe reduction in pulmonary function. Aim: To analyse whether aerosolized Pulmozyme® could reduce the number of bacterial infections in the lower respiratory airways of CF patients without chronic pulmonary infection. Methods: Patients were randomized either to aerosolized Pulmozyme® 2½ mg once daily or to no rhDNase treatment. The study period was 1 y, and the study was blinded for the Department of Clinical Microbiology. Results: Overall, the number of positive cultures was significantly higher in the untreated group (82%) compared with the treated group (72%) (p<0.05). The most striking difference was found for Staphylococcus aureus , with a prevalence of 30% in the untreated group compared with 16% in the treated group (χ 2 test, p<0.0001). Pulmonary function (FEV1) in the treated group showed a significant increase of 7.3% compared to 0.9% in the untreated group (p<0.05). Conclusion: Long‐term DNase treatment was beneficial to CF patients without chronic lower respiratory tract infection, leading to reduced demand for antibiotics and to improved lung function.